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Introduction 4 
Antimicrobial use (AMU) and antimicrobial resistance (AMR) have received a great deal of media 5 
attention, and with the government commissioned O’Neill report calling for a reduction of 6 
unnecessary AMU in agriculture (O’Neill 2015), there is a high level of scrutiny of  the livestock 7 
industry. Concerns exist that increased AMU in cattle might increase the prevalence of resistant 8 
pathogens (Saini et al., 2013), and although the importance of agricultural AMU in AMR risk to the 9 
human population is largely unknown (Tang et al., 2017), the potential “One Health” consequences 10 
of inappropriate AMU to both human and animal health means current and future AMU levels 11 
within the dairy industry require careful consideration. Dairy “herd health” is an approach to the 12 
veterinary care of dairy cattle applied at a population level, rather than the individual animal level 13 
(Green 2012). The focus of herd health is on preventing disease in the herd, often using a data driven 14 
approach. It follows that providing effective herd health advice to dairy farms alongside continuous 15 
monitoring and analysis has huge potential to reduce AMU on farm, by preventing disease, and 16 
therefore avoiding the need for antimicrobials. This herd health approach should also improve 17 
animal welfare, reduce cost to the farmer, and increase production – making reductions in AMU 18 
achieved by this route very sustainable. This article outlines key herd health approaches to common 19 
diseases on dairy farms that will result in a decrease in AMU, with a focus on those interventions 20 
most likely to result in the biggest reductions. 21 
Measuring antimicrobial use 22 
Monitoring and benchmarking AMU has been identified as an important intervention to incentivise 23 
reduced AMU in livestock (Speksnijder et al., 2015), and farm assurance schemes now often include 24 
  
an antimicrobial monitoring component (i.e. Red Tractor Farm Assurance). Much as clinical disease 25 
levels and economic outcomes are commonly calculated to assess the impact of herd health 26 
interventions, the reduction of AMU can also provide a straightforward, objective measurement of a 27 
key outcome of interest for UK dairy farms (see Figure 1). The freely available University of 28 
Nottingham AMU Calculator and Benchmarking Tool provides a simple platform for both 29 
veterinarians and farmers to assess AMU by both dose and mass based methodologies, as well as 30 
providing analysis of groups of farms (Hyde et al., 2017) (see Figure 2). A summary of approaches to 31 
measuring AMU is provided in Box 1. The Responsible Use of Medicines in Agriculture Alliance 32 
(RUMA) targets task force have created a series of targets for the UK dairy industry using standard 33 
European Medicines Agency metrics (RUMA 2017), as described in  34 
Table 1 The RUMA Target Task Force dairy sector targets compared with the most recent dairy 35 
antimicrobial usage (AMU) figures from~31% of the national dairy herd (VARRS 2017).  36 
 
Subject Current dairy AMU 
(VARRS 2017) 
RUMA Target 
(2020) 
1 HP-CIA injectables (mg/PCU) 0.76 0.54 
2 HP-CIA intra-mammary use (DCDVet) 0.22 0.17 
3 Intra-mammary tubes – dry cow (DCDVet) 0.68 0.67 
4 Intra-mammary tubes – lactating cow (DCDVet) 0.82 0.73 
5 Sealant tube usage (average number of courses per dairy cow)  0.70 
6 Total antimicrobial usage (mg/PCU) 17 21 
HP-CIA: Highest Priority critically important antimicrobials, mg/PCU: milligrams of antimicrobials used per 
population correction unit, DDDvet: defined daily dose, DCDvet: defined course dose 
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Medicines Directorate (VMD) and the Cattle Health and Welfare Group (CHAWG). 38 
Table 1 The RUMA Target Task Force dairy sector targets compared with the most recent dairy antimicrobial usage (AMU) 39 
figures from~31% of the national dairy herd (VARRS 2017).  40 
 
Subject Current dairy AMU 
(VARRS 2017) 
RUMA Target 
(2020) 
1 HP-CIA injectables (mg/PCU) 0.76 0.54 
2 HP-CIA intra-mammary use (DCDVet) 0.22 0.17 
3 Intra-mammary tubes – dry cow (DCDVet) 0.68 0.67 
4 Intra-mammary tubes – lactating cow (DCDVet) 0.82 0.73 
5 Sealant tube usage (average number of courses per dairy cow)  0.70 
6 Total antimicrobial usage (mg/PCU) 17 21 
  
HP-CIA: Highest Priority critically important antimicrobials, mg/PCU: milligrams of antimicrobials used per 
population correction unit, DDDvet: defined daily dose, DCDvet: defined course dose 
 41 
  
 42 
Motivating change 43 
The motivations for the use of antimicrobials are complex for both veterinarian and farmer, and the 44 
decision to administer or prescribe can be influenced by a range of often competing intrinsic and 45 
extrinsic factors. Intrinsic factors exert a powerful influence on behaviour. Experience, confidence, 46 
Measurements of antimicrobial use 
European medicines agency metrics 
mg/PCU = Milligrams of antimicrobial used per population correction unit 
DDDvet = Defined daily dose for animals  
DCDvet = Defined course dose for animals  
AMU can broadly be measured in two ways; by mass- or dose-based methodology. Mass-based 
methodologies measure the milligrams (mg) of antimicrobial used on a farm, per kg of animal at 
time of treatment; population correction unit (PCU). Dose based methodologies estimate the 
number of doses or courses of antimicrobial each animal receives, with injectable antimicrobials 
being assigned a standard dosage (i.e. Amoxicillin; 8mg/kg), and single treatments such as 
intramammary tubes counting as a single dose, regardless of mg. Detailed, farm level AMU in 
British dairy farms have recently been reported (Hyde et al., 2017) with injectable, footbath and 
oral antimicrobial use being shown to be strong drivers of AMU measured by mg/PCU, and 
intramammary treatments strong drivers of AMU measured by DDDvet and DCDvet. It is worth 
noting that topical antimicrobials such as sprays are not included in ESVAC metrics, and whilst dry 
cow therapy is included in DCDvet and mg/PCU metrics, it is not included in the calculation of 
DDDvet. One particular point to note when calculating AMU via ESVAC methodology is the use of 
the 425kg adult dairy cow weight, which has the potential to confuse producers if not explained 
that this is intended to represent the average weight at time of treatment rather than the actual 
weight of an adult cow.   
Whilst there has been some debate as to which metrics are likely to be most appropriate for the 
UK situation, there is currently no clear evidence as to which metrics are optimal for recording 
AMU, and ultimately incentivising reductions in both AMU and AMR. As the veterinarian analysing 
dairy herd mastitis will employ both SCC and clinical mastitis cases to inform herd level mastitis 
control decisions, it would appear prudent to apply a combination of both dose and mass-based 
methodologies when analysing AMU on farms. 
A detailed review evaluating metrics available for benchmarking AMU in the dairy industry is 
available from Mills et al., (2018).  
Box 1 A summary of metrics used to measure antimicrobial use on dairy farms 
  
attitude to risk and uncertainty all influence an individuals’ tendency to administer or prescribe, and 47 
in human medicine, these factors have been found to be some of the biggest determinants of 48 
antimicrobial prescribing rate (De Sutter et al., 2001). It would be unsurprising to find that the same 49 
was true in the farm animal context, where individual treatment decisions are often made by the 50 
farmer in the absence of direct veterinary supervision, and poor compliance with treatment 51 
protocols is common from a UK perspective (Sawant et al., 2005). There are also a range of extrinsic 52 
factors, including the clinical presentation, patient characteristics, economics and withhold times. 53 
Add to this the tendency of antimicrobial users towards defensive prescribing; the “precautionary 54 
principle”, encapsulated by the idea of administering antimicrobials “just in case”, and the pressure 55 
towards inappropriate use becomes clear. In spite of this, there is clear evidence of motivation 56 
amongst dairy farmers to reduce AMU, and it has also been shown that farmers consider veterinary 57 
surgeons to be the most influential source of information in this regard (Jones et al., 2015).  It is 58 
important to acknowledge this complexity when designing any strategy to motivate change in AMU 59 
on farm and to recognise the need to equip veterinary surgeons with appropriate communication 60 
skills training (e.g. motivational interviewing) (Bard et al., 2017; van Dijk et al., 2017) 61 
Proactive, multi-disciplinary, collaborative approaches from veterinarians to improve animal health 62 
alongside targeted reductions of the use of highest priority critically important antimicrobials (HP-63 
CIAs, which include 3rd and 4th generation cephalosporins, fluoroquinolones and colistin) have been 64 
shown to be effective, without significant effect on animal health outcomes (Tisdall et al., 2016; 65 
Turner et al., 2018). When farmers are drawn in as partners in the process and the competing 66 
factors which influence motivation are addressed, revisions in AMU policy as part of a proactive 67 
approach to herd health management becomes routine, and real behavioural change can occur. 68 
Farmer training on compliance and responsible use (such as the avoidance of HP-CIAs) is important, 69 
but information alone is insufficient to produce lasting behavioural change. The importance of 70 
intentional, one-to-one conversations with veterinary surgeons who are modelling best-practice, 71 
  
alongside the powerful influence of changing social norms and farmer role models should not be 72 
underestimated.  73 
Herd Health 74 
A summary of the key areas of dairy cow herd health that can lead to AMU reduction follows. A 75 
summary of key interventions for each area is provided in Box 2 and the potential impact in Figure 3. 76 
The following list summarises some key steps in dairy herd health that are likely to reduce inappropriate 
AMU on dairy farms 
 Udder health 
o Reduction in clinical mastitis incidence by implementing, for example, the AHDB dairy 
mastitis control plan 
o Cease use of injectable antimicrobial mastitis therapy as an adjunct to intra-mammary 
therapy and use NSAIDs instead 
o Implement selective dry cow therapy to reduce AMU and reduce Gram negative mastitis 
cases post-calving 
o Consider if on farm culture could be appropriate (e.g. low levels of Gram positive mastitis, 
and only if considering not treating Gram negative cases, which may not be economically 
worthwhile) 
 Lameness 
o Eliminate the use of antibiotic footbaths 
o Identify lameness prevalence and predominant lesion(s) 
o Ensure early detection and treatment 
o Treat claw horn disease with NSAIDs and block, not antimicrobials 
o Implement effective prevention strategies (e.g. improve cubicle comfort, improve hygiene) 
 Reproductive health 
o Monitor calving health, disease incidence, energy balance and levels of hypocalcaemia in 
order to effectively implement control strategies if above target levels.  
o Optimise transition cow nutrition, housing and management 
o Eliminate use of highest priority critically important antimicrobials (HP-CIAs) e.g. Ceftiofur 
 Youngstock 
o Monitor and ensure adequate passive transfer/colostrum intake 
o Optimise environmental conditions (e.g. bedding hygiene, ventilation) and nutrition 
o Avoid the use of antimicrobials in the treatment of calf diarrhoea, in the absence of clinical 
signs consistent with septicaemia and culture and sensitivity testing 
o Consider respiratory disease vaccination if appropriate 
o Eliminate the use of in-milk antimicrobials for prophylaxis/metaphylaxis 
 Infectious disease  
o Ascertain current disease status and implement appropriate biosecurity 
o Join or align with national initiatives (i.e. BVD eradication) where appropriate 
o Use vaccination to help control endemic disease when required (BVD, respiratory disease 
etc) 
Box 2 A summary of the key interventions to reduce inappropriate AMU on dairy farms using a herd health approach 
  
Udder health 77 
Mastitis remains one of the greatest challenges to the UK dairy industry (Bradley 2002), and can 78 
significantly affect AMU; being responsible for up to 68% of AMU when measured by dose based 79 
methodology (Kuipers et al., 2016). 4 out of the 6 RUMA dairy sector targets relate directly to 80 
mastitis therapy (Table 1), and by reducing both clinical mastitis and antimicrobial dry cow therapy a 81 
significant reduction in dairy farm AMU can be achieved (Kromker and Leimbach 2017). 82 
One method of mastitis reduction with a strong evidence base is the implementation of the AHDB 83 
Dairy Mastitis Control Plan (DMCP: www.dairy.ahdb.org.uk/technical-services/mastitis-control-plan), 84 
with plan users being shown to achieve a 20 percent reduction in clinical mastitis incidence 85 
compared with control farms (Green et al., 2007). Recent data suggests a 40 percent decrease in 86 
lactating cow intra-mammary AMU achieved via use of the DMCP (Bradley et al., 2017, Breen et al., 87 
2017) (Box 3). Generally unnecessary additional treatments such as the use of parenteral 88 
antimicrobials have no beneficial effects on the outcomes of mild/moderate clinical mastitis (Wenz 89 
et al., 2005), and the use of systemic antimicrobials can contribute to high AMU (mg/PCU) on dairy 90 
farms (Hyde et al., 2017). In contrast, the use of non-steroidal anti-inflammatory medication 91 
(NSAIDs) have clear benefits in the treatment of clinical mastitis and should be encouraged (Leslie 92 
and Petersson-Wolfe 2012). Gram negative mastitis may cure spontaneously without the use of 93 
antimicrobials, and as a result, interest in the use of on-farm culture systems to target treatment is 94 
increasing  (Lago et al., 2011).  Culture of mild clinical cases prior to antimicrobial treatment allows 95 
determination of bacterial cause avoiding unnecessary treatment. Caution is urged however, as due 96 
to decreased cure rates associated with delaying treatment of gram positive cases, this may not be 97 
cost effective for all UK farms (Down et al., 2017). The blanket use of antimicrobial dry cow therapy 98 
(DCT) regardless of infection status is challenging to justify, and selective DCT using recent somatic 99 
cell count and clinical mastitis data (for example having a somatic cell count <200,000 cells/ml and 100 
no clinical mastitis within the last 3 individual monthly recordings (Bradley et al., 2010)) can 101 
dramatically reduce AMU when measuring DCDvet. In addition, the use of selective DCT has been 102 
  
found to decrease prevalence of E.coli clinical mastitis cases post-calving (Bradley et al., 2010) 103 
compared with antimicrobial DCT, resulting in a potential reduction in disease incidence alongside a 104 
reduction in AMU.  105 
With a primary focus on the reduction of clinical mastitis incidence through the implementation of 106 
the DMCP, the reduction in generally unnecessary treatments such as parenteral therapy of 107 
mild/moderate cases, and adoption of selective DCT, it should be possible to dramatically reduce 108 
mastitis related AMU. It is worth noting reductions in intramammary usage primarily impacts dose or 109 
course based measures (rather than mass) as intra-mammary preparations typically have lower 110 
amounts of antimicrobial compared to systemic treatments. The role of the farm animal veterinarian 111 
must extend far beyond the treatment of individual cases of mastitis, and epidemiological data 112 
analysis skills in determining mastitis origin at herd level are likely to be extremely important in 113 
implementing effective mastitis control measures (Green et al., 2007).  114 
 115 
Lameness 116 
Lameness is a common presentation in dairy cattle and significant cause of financial loss and poor 117 
welfare. The most common causes of lameness are conditions of the foot, and these can be divided 118 
into claw horn lesions (sole haemorrhage/sole ulcer and white line disease) and soft tissue infections 119 
(interdigital phlegmon and digital dermatitis) (Archer et al., 2010). Investigations of lameness at a 120 
The implementation of the AHDB Dairy Mastitis Control Plan on a 600 cow dairy farm has been 
described as a case report (Breen et al., 2017), highlighting a reduction of clinical mastitis cases from a 
rate of 60-70 cases per 100 cows/year to less than 20 cases per 100 cows/year. Following analysis of 
herd level clinical mastitis and somatic cell count data, a focus on dry cow cubicle management as well 
as drying off technique resulted in dramatic reductions in both clinical and subclinical mastitis. This was 
paired with a reduction in AMU from 40mg/PCU and 14 DDDvet to 26mg/PCU and 7 DDDvet over a 3-
year period, highlighting the positive impact that herd level interventions can have on both animal 
health and welfare whilst simultaneously reducing AMU.  
Box 3. Example reductions in AMU through implementation of the AHDB Dairy Mastitis Control Plan 
  
herd level should aim to establish prevalence (for example by mobility scoring) and the predominant 121 
lesion types present on the farm by examining the feet of lame cows and analysing foot trimming 122 
records. 123 
A discussion of the causes of claw horn lesions is beyond the scope of this article, and has been 124 
undertaken elsewhere (Mahendran and Bell, 2015). However, it is clear bacterial infection is not 125 
thought to play a role in the pathogenesis (Newsome et al., 2016). It should not be necessary to 126 
treat claw horn lesions with antimicrobials and the best outcomes for the treatment of claw horn 127 
disease are achieved with the application of a foot block and the administration of a NSAID (Thomas 128 
et al., 2015). When detection and treatment are delayed, cure rates decline (Thomas et al., 2016), 129 
and regular mobility scoring has been described as an effective way of identifying early cases 130 
(Groenevelt et al., 2014). As well as better outcomes for the cows, early and effective treatment 131 
should prevent cases progressing to deep digital sepsis and other complications where 132 
antimicrobials would be required. Lame cows should not be given injectable antimicrobials as an 133 
alternative to examination of the foot. Prevention of the lesions should focus on improving lying 134 
comfort, reducing standing times, and reducing potential trauma (inappropriately sharp turns and 135 
high stocking rates), and regular foot trimming to quickly treat cows that do become lame. 136 
Soft tissue lameness is more likely to be bacterial in origin with interdigital phlegmon (foul) caused 137 
by Fusobacterium necrophorum and other bacteria and digital dermatitis thought to be caused by 138 
Treponema species (Maxwell et al., 2015). Clearly in these cases antimicrobial treatment may be 139 
justified, although only topical treatment is required for most digital dermatitis lesions (Laven and 140 
Logue 2006). Cure rates remain low with common topical and systemic treatments and improved 141 
antimicrobial or non-antimicrobial treatment protocols are required and may be developed (Evans et 142 
al., 2016). Prevention should focus on improving environmental hygiene and in particular underfoot 143 
conditions. Regular use of a disinfectant foot bath is an essential measure in the control of digital 144 
dermatitis with evidence to support the use of both formalin and copper sulphate products (Bell et 145 
  
al., 2014). Care needs to be taken with either product, formalin is a carcinogen and alongside 146 
concerns of environmental accumulation there is evidence that heavy metals such as copper may 147 
select for AMR (Hobman & Crossman, 2018). Anecdotally, some herds have used antibiotic footbaths 148 
to control digital dermatitis. This practice is associated with extremely high levels of AMU, with 149 
farms using antibiotic footbaths being far more likely to be “high users” overall ( Hyde et al., 2017) 150 
and is no longer considered acceptable or necessary (Bell et al.,2017). Where the prevalence of 151 
acute digital dermatitis is high and/or disinfectant footbaths would cause too much discomfort to 152 
affected cows then targeted topical treatment (for example the application of oxytetracycline spray) 153 
of individual animals should be carried out, resulting in a significantly decreased level of AMU 154 
compared with herd level antibiotic footbathing.  155 
Reproduction 156 
Postpartum reproductive disease is relatively common in dairy cows, and the combination of 157 
reduced fertility, increased risk of culling, and increased AMU associated with these conditions 158 
makes their control and prevention extremely important (Gilbert 2016). The treatment of 159 
postpartum diseases such as metritis have historically involved the use of ceftiofur, however the use 160 
of HP-CIAs essential for human medicine largely on the basis of zero milk withdrawal is extremely 161 
difficult to defend. Many alternatives to HP-CIAs exist, and these should be considered wherever 162 
possible, particularly in light of recent farm assurance changes such as the Red Tractor antibiotic 163 
standards. Practitioners should be aware that the swapping of HP-CIAs to non-critical alternatives 164 
may result in an increase in overall AMU as measured by mass based methodologies, due to the 165 
relatively low dosing requirements of HP-CIAs (i.e. ceftiofur dosage: 1mg/kg, amoxicillin: 8mg/kg). 166 
Also to be considered are bulk tank residue failures if farmers’ are not adequately informed of milk 167 
withdrawal requirements of HP-CIA alternatives, as well as the significant risks posed by the feeding 168 
of antimicrobial waste milk to calves as a route of disposal (Ricci et al., 2017). Treatment of bacterial 169 
reproductive disease such as metritis with antimicrobials can be justified, however cases of retained 170 
fetal membranes should not need antimicrobial treatment in the absence of pyrexia (Drillich et al., 171 
  
2006). Whilst the treatment of clinical endometritis with intrauterine cephapirin has been shown in 172 
several studies to improve reproductive outcomes (Hyde & Brennan, 2017), the use of antimicrobial 173 
treatments for reasons other than cow health may be challenging to justify. Alternatives to 174 
antimicrobials such as prostaglandin treatments are widely used, although their efficacy in improving 175 
reproductive outcomes have been called into question (Haimerl et al., 2013). It is far more effective 176 
to prevent diseases such as endometritis than rely on treatment options with limited evidence of 177 
efficacy.   178 
The prevention of postpartum reproductive disease focusses on maintaining dry matter intake over 179 
the dry period, reducing negative energy balance and improving hygiene (Gilbert 2016), as well as 180 
minimising social group changes . A diagnostic approach to transition cow disease should focus on 181 
housing, management and nutrition. Key aspects are ensuring adequate feed space, ration 182 
composition and stocking density to maximise feed intake as well as control of hypocalcaemia and 183 
negative energy balance, all of which are areas practitioners can regularly monitor.  A minimum feed 184 
space of 76cm per cow has been recommended for transition cows (Cook and Nordlund 2004), with 185 
a minimum required area per cow of 1.25m2/1,000 litres/year (Green et al., 2007) in loose housing. 186 
Cows should be assessed for body condition, lameness and infectious disease.  Consideration can be 187 
given to the use of preventive treatments, such as a monensin (although it is worth noting monensin 188 
is also an antibiotic) or immune restoratives (Ruiz et al., 2017), although recent studies suggest the 189 
potential for immune restorative products such as pegbovigrastim to have significant detriment to 190 
cow health (Zinicola et al., 2018).  191 
Both pre-partum energy balance monitoring with non-esterified fatty acid (NEFA) testing, and post-192 
partum with beta-hydroxybutyrate (BHB) testing as a herd level strategy to identify both individual 193 
and herd level issues is of value (Ospina et al., 2013). For example, early identification of ketotic 194 
cows via BHB testing and subsequent treatment with propylene glycol might prevent downstream 195 
complications of ketosis such as metritis and left-displacement of the abomasum (LDAs). 196 
  
Furthermore, the regular monitoring of these metabolites at a herd level can be invaluable in 197 
determining where attention best be focused to prevent post-partum reproductive disease.  198 
Youngstock 199 
Neonatal calf diarrhoea and bovine respiratory disease (BRD) are common causes of morbidity and 200 
mortality in calves, and both are frequently treated with antimicrobials. Whilst calf AMU often has a 201 
relatively minor effect on overall herd AMU figures, these diseases represent a significant cost both 202 
in terms of economics and welfare, and remain a great opportunity for AMU reduction relative to 203 
calves. Treatment decisions are complicated by mixed viral, bacterial and protozoal aetiologies, and 204 
patterns of clinical signs which lack specificity for each cause. In addition, a wide range of risk factors 205 
relating to the housing environment and husbandry practices are at play. The combination of 206 
uncertainty surrounding a specific diagnosis, the relatively low cost and practical simplicity of 207 
antimicrobial therapy, and an aversion to risk, potentially all contribute to defensive prescribing in 208 
these cases.  209 
The use of calf-side diagnostics can help predominant pathogen identification in cases of calf 210 
diarrhoea, though mixed infections are commonly present. Control should focus on maximising calf 211 
immunity through effective passive transfer of colostral immunity and reducing the pathogen 212 
challenge by improving environmental hygiene (Lorenz et al., 2011). Therapy should focus on fluid 213 
rehydration by oral or intravenous routes, dependant on the degree of shock (Meganck et al., 2014). 214 
NSAIDs are also appropriate, where adequate renal perfusion is maintained. Antimicrobial therapy 215 
of neonatal calf diarrhoea with oral boluses or parenteral injections are not needed, with the 216 
exception of severely sick animals, for example those affected with septicaemia associated with E. 217 
coli in the first few days of life (Constable 2004). 218 
Control of BRD should again focus on achieving adequate passive transfer as well as improving 219 
environmental conditions and nutrition (for example improved ventilation, increased frequency of 220 
bedding and adequate energy intake) (Gorden and Plummer 2010). In closed herds identifying the 221 
  
causative primary pathogens may be of value to inform preventive strategies. Sampling of acute 222 
cases of respiratory disease using broncho-alveolar lavage (BAL), trans-tracheal washes and 223 
conjunctival/nasopharyngeal swabs are techniques underused in clinical practice to inform 224 
treatment decisions. Culture and sensitivity results from post-mortem submissions may have more 225 
limited value in informing treatment decisions because they often represent chronic cases and 226 
treatment failures rather than the primary agent, however post-mortem examination can be 227 
extremely valuable when cases are appropriately selected. Retrospective or ideally paired serology 228 
of cohorts undergoing the same management system can be useful to identify predominant 229 
pathogens, but has less value therapeutically. An extensive range of vaccines are available for the 230 
common causes of respiratory disease, although are unlikely to completely prevent disease in the 231 
presence of poor environmental conditions (Sherwin and Down 2018). Similarly, vaccination of dams 232 
to provide immunity to calves for the causative agents of diarrhoea will not be effective if colostrum 233 
and environmental management is inadequate.   234 
Prophylactic use of antimicrobials should be avoided, with a clear emphasis placed on preventing 235 
disease. The use of tetracyclines to medicate milk powder as a control strategy for BRD does not 236 
represent responsible AMU (VMD, 2013), particularly when effective control strategies, including 237 
vaccination are available. The potential for co-selection for resistance to cephalosporins in cattle is 238 
well recognised and should increase concern regarding the unnecessary and overuse of tetracyclines 239 
(Kanwar et al., 2014). The routine monitoring of calf serum total proteins and colostrum quality will 240 
enable the early detection and subsequent investigation of issues within the colostrum management 241 
process, and bacteriological analysis of colostrum may also be of interest if hygiene failures are 242 
suspected. There is great potential for the veterinarian to have significant impact on calf health by 243 
improving management factors such as colostrum management, which will lead to measurable 244 
improvements in calf health and consequently reductions in AMU.  245 
  
Infectious disease 246 
Infectious disease control has been a significant part of veterinary surgeon led herd health planning 247 
over many years. The drivers for infectious disease control include reducing disease (production, 248 
economic and welfare impacts) and increasing stock value (trade). Key single agent infectious 249 
diseases important in dairy herds include BVD, Bovine herpes virus (BHV), Leptospirosis, Johnes 250 
Disease and Bovine Tuberculosis (bTB). BVD exacerbates calf disease through immunosuppression 251 
(Lanyon et al., 2014), and BHV can cause pneumonia (IBR) and abortions (Graham 2013), and whilst 252 
both BVD and BHV are viral infections, it is likely that AMU will increase in the face of disease. 253 
Johne’s Disease is bacterial in origin but considered untreatable, again increased AMU seems likely 254 
due to the increased risk of other diseases (Tiwari et al., 2006). Bovine TB has the potential to 255 
indirectly increase AMU through restrictions on livestock sales, resulting in overstocking of calves, or 256 
restocking through purchases increasing infectious disease risk.  257 
A number of disease control and eradication strategies and schemes are available, and it is plausible 258 
that good control of single agent infectious diseases are not only good for health and productivity 259 
but are also likely to lead to reductions in AMU. Regular bulk tank milk serological screening and the 260 
adoption of appropriate biosecurity and/or vaccination strategies are commonly advocated for BVD, 261 
IBR and Leptospirosis, although all approaches have their limitations. BVD eradication is supported 262 
by legislation in Scotland and industry led schemes in England (BVD Free) and Wales (Gwaredu BVD). 263 
Johne’s disease control requires control plan compliance over a sustained period of time, with 264 
advice available from the National Action Group on Johne’s (actionjohnesuk.org). Bovine TB control 265 
is achieved through statutory controls, and accreditation schemes (such as CHeCS) also exist and 266 
again biosecurity is essential in control. 267 
Retailers and milk buyers 268 
Milk price banding has been used to pay for milk constituents for many years, and to incentivise 269 
somatic cell count control since 1994. The milk price received and contractual relationship now 270 
  
extends much more widely to cover AMU and herd health through aligned retailer contracts, which 271 
create a direct relationship between retailer and supplier. These aligned contracts give the retailer 272 
direct influence in the supply chain, allowing the retailer an opportunity to address issues such as 273 
health, welfare and medicine residues, with the aim of building consumer trust. Contracts require 274 
dairy farms to meet minimum standards and higher standards can be incentivised. Two methods of 275 
AMU data collection exist – reporting directly by farmers, or reporting of antimicrobial sales by the 276 
veterinary practice. Whichever collection method is used, benchmarking identifies AMU by type and 277 
class. 278 
AMU reporting can be used to influence antimicrobial selection, with retailers restricting access to 279 
highest priority critically important antimicrobials, and this approach has been adopted from June 280 
2018 by the Red Tractor Assurance Scheme. Treatment decision making is influenced through the 281 
encouragement of selective dry cow therapy, which requires somatic cell count recording and 282 
control. Farms with relatively high use of therapeutic antimicrobials can be identified as benefit is 283 
likely to be seen from both improved disease control as well as implementing rational treatment 284 
protocols if they do not yet exist. Benefits from an AMU reduction plan should be accrued by the 285 
retailer (less reputation risk), the processor (less residue risk), the farmer (less cost), the cow (less 286 
disease) and the veterinarian (herd health opportunities). Aligned contracts encourage farmer 287 
engagement through benchmarking and incentives (potential for price or volume bonuses from high 288 
performance) and risk (contracts may be lost from underperformance). While retailer contracts are 289 
driving change and AMU reduction, this change should be beneficial to all, and is simply another step 290 
towards increased preventive health. 291 
Summary 292 
The responsible use of antimicrobials on dairy farms is an important issue. By monitoring AMU and 293 
applying the principles of herd health to reducing disease associated with high AMU, significant 294 
decreases in AMU can be achieved. Reductions in AMU achieved by reducing disease are likely to be 295 
  
sustainable as well as good for animal welfare, farm profitability and production, whilst limiting the 296 
dissemination of antimicrobials into the environment, not to mention an excellent opportunity for 297 
veterinarians interested in providing a herd health consultancy service to their farm clients. 298 
Veterinarians have a great role to play in the training of farmers, and are clearly gatekeepers in AMU 299 
prescription with an obligation to be in control of what is being prescribed to farms. Benchmarking 300 
at practice level is an easy and effective method of identifying high usage farms and allows effective 301 
AMU reductions to be rapidly achieved through targeted herd health interventions. Freely 302 
downloadable tools are available both to measure and benchmark AMU on farms, and should 303 
feature as a routine component of a herd health review, enabling veterinarians to engage with high 304 
use farms, and reduce AMU by reducing disease incidence through proactive herd health 305 
interventions. 306 
Figures 307 
 308 
Figure 1 A diagram illustrating high antimicrobial use on an example dairy farm 309 
 310 
  
 311 
Figure 2 An illustrated guide to using the AHDB/University of Nottingham antimicrobial use 312 
calculator (available to download for free from www.dairy.ahdb.org.uk/technical-313 
  
information/animal-health-welfare/amu-calculator) and Benchmarking tool (available to download 314 
for free from www.dairy.ahdb.org.uk/resources-library/technical-information/health-welfare/amu-315 
benchmarking-tool) to assess AMU on the example farm (figure 1), and benchmark against other 316 
farms 317 
  
 318 
Figure 3 A diagram illustrating the scale of antimicrobial use reduction that could be achieved in the 319 
example herd (Figure 1) by implementing the advice in the article 320 
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